de UBS Group BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 50.8 M | Comprar |
5,078,280
+134,286
| +3% | +USD 1.21 M | 0.01% | 1729 |
|
|
2026
Q1 | USD 47.1 M | Vender |
4,943,994
-319,920
| -6% | -USD 2.48 M | 0.01% | 1706 |
|
|
2025
Q4 | USD 41.1 M | Vender |
5,263,914
-703,823
| -12% | -USD 5.09 M | 0.01% | 1834 |
|
|
2025
Q3 | USD 45.3 M | Comprar |
5,967,737
+353,086
| +6% | +USD 2.94 M | 0.01% | 1736 |
|
|
2025
Q2 | USD 50.3 M | Comprar |
5,614,651
+3,211,465
| +134% | +USD 29.9 M | 0.01% | 1518 |
|
|
2025
Q1 | USD 18 M | Comprar |
2,403,186
+2,162,834
| +900% | +USD 17.4 M | ﹤0.01% | 2443 |
|
|
2024
Q4 | USD 1.81 M | Vender |
240,352
-184,667
| -43% | -USD 1.4 M | ﹤0.01% | 4815 |
|
|
2024
Q3 | USD 3.23 M | Comprar |
425,019
+33,534
| +9% | +USD 255 k | ﹤0.01% | 3515 |
|
|
2024
Q2 | USD 2.42 M | Vender |
391,485
-605,070
| -61% | -USD 3.34 M | ﹤0.01% | 3573 |
|
|
2024
Q1 | USD 5.06 M | Comprar |
996,555
+311,567
| +45% | +USD 1.75 M | ﹤0.01% | 2960 |
|
|
2023
Q4 | USD 4.1 M | Comprar |
684,988
+379,037
| +124% | +USD 2.2 M | ﹤0.01% | 3000 |
|
|
2023
Q3 | USD 2.17 M | Vender |
305,951
-108,883
| -26% | -USD 782 k | ﹤0.01% | 3367 |
|
|
2023
Q2 | USD 2.92 M | Comprar |
414,834
+8,954
| +2% | +USD 71.9 k | ﹤0.01% | 3141 |
|
|
2023
Q1 | USD 3.39 M | Vender |
405,880
-213,548
| -34% | -USD 2.06 M | ﹤0.01% | 2886 |
|
|
2022
Q4 | USD 7.11 M | Comprar |
619,428
+439,894
| +245% | +USD 5.49 M | ﹤0.01% | 2176 |
|
|
2022
Q3 | USD 2.26 M | Comprar |
179,534
+27,096
| +18% | +USD 349 k | ﹤0.01% | 3051 |
|
|
2022
Q2 | USD 1.61 M | Comprar |
152,438
+9,290
| +6% | +USD 95.8 k | ﹤0.01% | 3327 |
|
|
2022
Q1 | USD 2.33 M | Vender |
143,148
-389,502
| -73% | -USD 6.25 M | ﹤0.01% | 3290 |
|
|
2021
Q4 | USD 7.38 M | Comprar |
532,650
+194,262
| +57% | +USD 2.57 M | ﹤0.01% | 2425 |
|
|
2021
Q3 | USD 4.86 M | Comprar |
338,388
+159,369
| +89% | +USD 2.51 M | ﹤0.01% | 2702 |
|
|
2021
Q2 | USD 2.83 M | Vender |
179,019
-10,397
| -5% | -USD 141 k | ﹤0.01% | 3237 |
|
|
2021
Q1 | USD 1.93 M | Vender |
189,416
-338,457
| -64% | -USD 3.49 M | ﹤0.01% | 3599 |
|
|
2020
Q4 | USD 3.93 M | Vender |
527,873
-909,182
| -63% | -USD 4.69 M | ﹤0.01% | 2709 |
|
|
2020
Q3 | USD 4.94 M | Comprar |
1,437,055
+1,278,179
| +805% | +USD 5.48 M | ﹤0.01% | 2221 |
|
|
2020
Q2 | USD 757 k | Vender |
158,876
-4,924,362
| -97% | -USD 19.7 M | ﹤0.01% | 3755 |
|
|
2020
Q1 | USD 10.2 M | Vender |
5,083,238
-405,049
| -7% | -USD 1.12 M | ﹤0.01% | 1401 |
|
|
2019
Q4 | USD 18.9 M | Comprar |
5,488,287
+2,450,478
| +81% | +USD 6.16 M | 0.01% | 1421 |
|
|
2019
Q3 | USD 8.7 M | Comprar |
3,037,809
+835,015
| +38% | +USD 2.6 M | ﹤0.01% | 1876 |
|
|
2019
Q2 | USD 8.35 M | Comprar |
2,202,794
+1,691,681
| +331% | +USD 10.2 M | ﹤0.01% | 1909 |
|
|
2019
Q1 | USD 4.16 M | Comprar |
511,113
+385,569
| +307% | +USD 3.3 M | ﹤0.01% | 2359 |
|
|
2018
Q4 | USD 1.01 M | Comprar |
125,544
+13,659
| +12% | +USD 106 k | ﹤0.01% | 3674 |
|
|
2018
Q3 | USD 854 k | Comprar |
111,885
+48,646
| +77% | +USD 327 k | ﹤0.01% | 3992 |
|
|
2018
Q2 | USD 362 k | Vender |
63,239
-228,140
| -78% | -USD 1.26 M | ﹤0.01% | 4555 |
|
|
2018
Q1 | USD 1.39 M | Comprar |
291,379
+191,157
| +191% | +USD 982 k | ﹤0.01% | 3433 |
|
|
2017
Q4 | USD 493 k | Vender |
100,222
-13,892
| -12% | -USD 67.3 k | ﹤0.01% | 4301 |
|
|
2017
Q3 | USD 598 k | Comprar |
114,114
+50,635
| +80% | +USD 259 k | ﹤0.01% | 4085 |
|
|
2017
Q2 | USD 353 k | Vender |
63,479
-8,562
| -12% | -USD 52.2 k | ﹤0.01% | 4375 |
|
|
2017
Q1 | USD 605 k | Vender |
72,041
-27,762
| -28% | -USD 193 k | ﹤0.01% | 3907 |
|
|
2016
Q4 | USD 632 k | Comprar |
99,803
+11,547
| +13% | +USD 60.1 k | ﹤0.01% | 3932 |
|
|
2016
Q3 | USD 389 k | Comprar |
88,256
+4,086
| +5% | +USD 16.3 k | ﹤0.01% | 4082 |
|
|
2016
Q2 | USD 239 k | Comprar |
84,170
+11,335
| +16% | +USD 35.2 k | ﹤0.01% | 4435 |
|
|
2016
Q1 | USD 206 k | Vender |
72,835
-68,568
| -48% | -USD 304 k | ﹤0.01% | 4476 |
|
|
2015
Q4 | USD 1.46 M | Comprar |
141,403
+69,068
| +95% | +USD 687 k | ﹤0.01% | 3100 |
|
|
2015
Q3 | USD 825 k | Comprar |
72,335
+2,651
| +4% | +USD 35.4 k | ﹤0.01% | 3531 |
|
|
2015
Q2 | USD 1.04 M | Vender |
69,684
-200
| -0.3% | -USD 2.27 k | ﹤0.01% | 3532 |
|
|
2015
Q1 | USD 631 k | Vender |
69,884
-690
| -1% | -USD 7.14 k | ﹤0.01% | 3942 |
|
|
2014
Q4 | USD 858 k | Comprar |
+70,574
| Nuevas | +USD 780 k | ﹤0.01% | 3695 |
|
Otros fondos que tienen BCRX en su cartera
Posición de UBS Group en BCRX: resumen de T2 2026
UBS Group aumentó su participación en BioCryst Pharmaceuticals (BCRX) en 2.7% durante T2 2026, al comprar aproximadamente USD 1.21 M y elevar la posición a 5,078,280 acciones con un valor de USD 50.8 M. La posición representa 0.01% de la cartera y ocupa el puesto #1729.
UBS Group reportó por primera vez una posición en BCRX en T4 2014 y la ha mantenido durante 47 trimestres desde entonces. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, UBS Group tenía 5,078,280 acciones de BioCryst Pharmaceuticals con un valor de USD 50.8 M.
- UBS Group compró 134,286 acciones de BioCryst Pharmaceuticals en T2 2026, por un monto estimado de USD 1.21 M.
- BioCryst Pharmaceuticals representó 0.01% de la cartera de UBS Group en T2 2026 y fue su posición número 1729.
- UBS Group reportó por primera vez una posición en BioCryst Pharmaceuticals en T4 2014 y la ha mantenido durante 47 trimestres desde entonces.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de UBS Group correspondiente a T2 2026, presentado el 13 ago 2026.